{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:00:29Z","timestamp":1761156029869},"reference-count":17,"publisher":"Computers, Materials and Continua (Tech Science Press)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["oncol res"],"published-print":{"date-parts":[[2015,11,25]]},"abstract":"<jats:p>Radiation recall syndrome is an acute inflammatory reaction developing at anatomical sites of previously irradiated tissue, weeks to months after the completion of radiation therapy. The distribution pattern of inflammation typically involves, and remains limited to, the boundaries\n of prior radiation treatment fields. Several classical chemotherapy drugs have been reported to have the potential for causing radiation recall syndrome. With the increasing availability and expanding use of novel biologic and targeted therapy anticancer drugs, isolated reports of radiation\n recall syndrome secondary to this class of agents are starting to appear in the literature. We describe a case of everolimus-induced radiation recall pneumonitis in a patient with metastatic renal cell cancer.<\/jats:p>","DOI":"10.3727\/096504015x14400775740416","type":"journal-article","created":{"date-parts":[[2015,11,21]],"date-time":"2015-11-21T16:58:30Z","timestamp":1448125110000},"page":"321-324","source":"Crossref","is-referenced-by-count":10,"title":["Radiation Recall Pneumonitis During Systemic Treatment With Everolimus"],"prefix":"10.32604","volume":"22","author":[{"given":"Douglas","family":"Clark","sequence":"first","affiliation":[{"name":"Saint Francis Cancer Treatment Center, Grand Island, NE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dron","family":"Gauchan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Norvell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Sitki","family":"Copur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","reference":[{"key":"b1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ctrv.2005.07.008","article-title":"Radiation recall: A well-recognized but neglected phenomenon","volume":"31","year":"2005","journal-title":"Cancer Treat. Rev."},{"key":"b2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1634\/theoncologist.2009-0090","article-title":"Radiation recall with anticancer agents","volume":"15","year":"2010","journal-title":"Oncologist"},{"key":"b3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-8140(01)00328-0","article-title":"Characterizing the phenomenon of radiation recall dermatitis","volume":"59","year":"2001","journal-title":"Radiother. Oncol."},{"key":"b4","first-page":"565","article-title":"Radiation recall pneumonitis induced by gefitinib (Iressa): A case report","volume":"41","year":"2003","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"b5","first-page":"18","article-title":"Frequency of radiation recall dermatitis in adult cancer patients","volume":"28","year":"2005","journal-title":"Onkologie"},{"key":"b6","first-page":"744","article-title":"Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer","volume":"9","year":"2008","journal-title":"JOP"},{"key":"b7","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdq444","article-title":"Recall pneumonitis during systemic treatment with sunitinib","volume":"21","year":"2010","journal-title":"Ann. Oncol."},{"key":"b8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/annonc\/mdq741","article-title":"Total recall of radiotherapy with mTOR inhibitors: A novel and potentially frequent side-effect?","volume":"22","year":"2011","journal-title":"Ann. Oncol."},{"key":"b9","doi-asserted-by":"crossref","first-page":"abs 403","DOI":"10.1200\/jco.2015.33.7_suppl.403","article-title":"Initial results from ASSURE(E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led NCTN phase III trial","volume":"33","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"b10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1158\/1078-0432.CCR-08-1019","article-title":"Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature","volume":"15","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"b11","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1038\/sj.onc.1208715","article-title":"Enhanced radiation damage of tumor vasculature by mTOR inhibitors","volume":"24","year":"2005","journal-title":"Oncogene"},{"key":"b12","first-page":"214","article-title":"The mTOR inhibitor rapamycin suppresses DNA double-strand break repair","volume":"175","year":"2011","journal-title":"Radiat. Res."},{"key":"b13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"b14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0360-3016(00)00783-5","article-title":"Radiation pneumonitis in lung cancer patients: A retrospective study of risk factors and the long term prognosis","volume":"49","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"b15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2004.02.015","article-title":"Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer","volume":"71","year":"2004","journal-title":"Radiother. Oncol."},{"key":"b16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/annonc\/mdq741","article-title":"Total recall of radiotherapy with mTor inhibitors: A novel and potentially frequent side effect","volume":"22","year":"2011","journal-title":"Ann. Oncol."},{"key":"b17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.radonc.2014.08.030","article-title":"Radiation recall dermatitis with the everolimus examestane combination ten years after adjuvant whole breast radiotherapy","volume":"112","year":"2014","journal-title":"Radiother. Oncol."}],"container-title":["Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/cog\/or\/2015\/00000022\/f0020005\/art00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T10:06:25Z","timestamp":1658138785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.3727\/096504015X14400775740416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,25]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11,25]]}},"alternative-id":["0965-0407(20151125)22:5L.321;1-"],"URL":"https:\/\/doi.org\/10.3727\/096504015x14400775740416","relation":{},"ISSN":["0965-0407"],"issn-type":[{"value":"0965-0407","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11,25]]}}}